Copyright
©The Author(s) 2024.
World J Clin Oncol. Aug 24, 2024; 15(8): 1033-1047
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1033
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1033
Variables | OS | |
HR (95%CI) | P value | |
Univariate analysis | ||
Gender (male vs female) | 0.922 (0.729-1.165) | 0.496 |
Age (< 65 vs ≥ 65) | 1.315 (1.080-1.604) | 0.007 |
Clinical stage | ||
I | 1 (Reference) | |
II | 2.876 (1.735-4.768) | 0.000 |
III | 8.712 (5.601-13.552) | 0.000 |
T stage | ||
T1 | 1 (Reference) | |
T2 | 1.693 (0.889-3.227) | 0.019 |
T3 | 4.438 (2.634-7.478) | 0.000 |
T4 | 6.330 (3.981-10.065) | 0.000 |
N stage | ||
N0 | 1 (Reference) | |
N1 | 2.330 (1.667-3.257) | 0.000 |
N2 | 3.239 (2.383-4.401) | 0.000 |
N3 | 5.201 (3.957-6.836) | 0.000 |
Location | ||
Cardia | 1 (Reference) | |
Gastric body | 1.306 (1.025-1.664) | 0.031 |
Antrum of stomach | 1.698 (1.276-2.261) | 0.000 |
Pathological type (adenocarcinoma vs other) | 1.209 (0.807-1.813) | 0.358 |
Differentiation (well, high and medium vs moderate to low and poor) | 1.776 (1.392-2.265) | 0.000 |
Borrmann type (III vs other) | 0.579 (0.462-0.724) | 0.000 |
Size (< 5 vs ≥ 5) | 0.403 (0.329-0.494) | 0.000 |
AFP (positive vs negative) | 1.929 (1.520-2.448) | 0.000 |
CEA (positive vs negative) | 3.155 (2.584-3.851) | 0.000 |
CA125 (positive vs negative) | 2.521 (2.067-3.074) | 0.000 |
CA19-9 (positive vs negative) | 3.489 (2.847-4.276) | 0.000 |
Multivariate analysis | ||
Age (< 65 vs ≥ 65) | 1.225 (0.999-1.501) | 0.052 |
Clinical stage | ||
I | 1 (Reference) | |
II | 2.102 (1.248-3.540) | 0.005 |
III | 4.860 (2.988-7.907) | 0.000 |
Location | ||
Cardia | 1 (Reference) | |
Gastric body | 1.531 (1.187-1.976) | 0.051 |
Antrum of stomach | 1.092 (0.847-1.406) | 0.498 |
Differentiation (well, high and medium vs moderate to low and poor) | 1.212 (0.940-1.564) | 0.139 |
Borrmann type (III vs other) | 0.873 (0.688-1.108) | 0.265 |
Size (< 5 vs ≥ 5) | 1.269 (1.020-1.578) | 0.032 |
AFP (positive vs negative) | 1.728 (1.359-2.198) | 0.000 |
CEA (positive vs negative) | 2.037 (1.646-2.522) | 0.000 |
CA125 (positive vs negative) | 1.739 (1.416-2.135) | 0.000 |
CA19-9 (positive vs negative) | 1.910 (1.535-2.377) | 0.000 |
- Citation: Sun AH, Zhang XY, Huang YY, Chen L, Wang Q, Jiang XC. Prognostic value and predictive model of tumor markers in stage I to III gastric cancer patients. World J Clin Oncol 2024; 15(8): 1033-1047
- URL: https://www.wjgnet.com/2218-4333/full/v15/i8/1033.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i8.1033